Who are C21's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SAR408701, CHS-1420, SM03, TP-03.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/c21.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

C21 — Competitive Intelligence Brief

C21 (C21) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD40 agonist. Area: Oncology.

phase 3 CD40 agonist CD40 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

C21 (C21) — Vicore Pharma AB. C21 is a CD40 agonist that activates the CD40 receptor on immune cells to enhance anti-tumor immune responses.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
C21 TARGET	C21	Vicore Pharma AB	phase 3	CD40 agonist	CD40
SAR408701	SAR408701	Sanofi	phase 3	Bispecific antibody; CD40/4-1BB agonist	CD40 and 4-1BB (TNFRSF9)
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
SM03	SM03	SinoMab BioScience Ltd	phase 3	CD40 ligand inhibitor (monoclonal antibody)	CD40L (CD154)
TP-03	TP-03	Tarsus Pharmaceuticals, Inc.	phase 3	monoclonal antibody	CD40

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD40 agonist class)

Vicore Pharma AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). C21 — Competitive Intelligence Brief. https://druglandscape.com/ci/c21. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab